Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in 131I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin’s lymphoma

Original Article



Radioimmunotherapy (RIT) for relapsed non-Hodgkin’s lymphoma is emerging as a promising treatment strategy. Myelosuppression is the dose-limiting toxicity and may be particularly problematic in patients heavily pretreated with chemotherapy. Reliable dosimetry is likely to minimise toxicity and improve treatment efficacy, and the aim of this study was to elucidate the complex problems of dosimetry of RIT by using an integrated SPECT/CT system.


As a part of a clinical trial of 131I-anti-CD20 rituximab RIT of non-Hodgkin’s lymphoma, we employed a patient-specific prospective dosimetry method utilising the whole-body effective half-life of antibody and the patient’s ideal weight to calculate the administered activity for RIT corresponding to a prescribed radiation absorbed dose of 0.75 Gy to the whole body. A novel technique of quantitation of bone marrow uptake with hybrid SPECT/CT imaging was developed to validate this methodology by using post-RIT extended imaging and data collection.


A strong, statistically significant correlation (p=0.001) between whole-body effective half-life of antibody and effective marrow half-life was demonstrated. Furthermore, it was found that bone marrow activity concentration was proportional to administered activity per unit weight, height or body surface area (p<0.001).


The results of this study show the proposed whole-body dosimetry method to be valid and clinically applicable for safe, effective RIT.


Non-Hodgkin’s lymphoma Rituximab Radioimmunotherapy Dosimetry SPECT/CT 


  1. 1.
    Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkin’s lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm 2003;18:513–24.CrossRefPubMedGoogle Scholar
  2. 2.
    Wahl RL. Iodine-131 anti-B1 antibody therapy in non-Hodgkin’s lymphoma: dosimetry and clinical implications. J Nucl Med 1998;39(suppl):1S–9S.PubMedGoogle Scholar
  3. 3.
    Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998;39(suppl):9S–16S.Google Scholar
  4. 4.
    Wiseman GA, Leigh B, Lamonica D, Kornmehl E, Spies SM, Silverman DHS, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002;94:1349–57.PubMedGoogle Scholar
  5. 5.
    DeNardo SJ, DeNardo GL, Kukis D, Shen S, Kroger L, DeNardo DA, et al. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumour regression in patients with lymphoma. J Nucl Med 1999;40:303–10Google Scholar
  6. 6.
    Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay R, Hoffman R, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 1989;15:784–95.PubMedGoogle Scholar
  7. 7.
    Rizzieri DA, Akabani G, Zalutsky M, Coleman RE, Metzler SD, Bowsher JE, et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood 2004;104:642–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689–94.PubMedGoogle Scholar
  9. 9.
    Macey DJ, DeNardo SJ, DeNardo GL, DeNardo DA, Shen S. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy. Clin Nucl Med 1995;20:117–25.PubMedGoogle Scholar
  10. 10.
    Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538–46.PubMedGoogle Scholar
  11. 11.
    Bouchet LG, Bolch WE, Howell RW, Rao DV. S values for radionuclides localized within the skeleton. J Nucl Med 2000;41:189–212.Google Scholar
  12. 12.
    Bolch WE, Patton PW, Rajon DA, Shah AP, Jokisch DW, Inglis BA. Considerations of marrow cellularity in 3-dimensional dosimetric models of the trabecular skeleton. J Nucl Med 2002;43:97–108.PubMedGoogle Scholar
  13. 13.
    Stabin MG, Eckerman KF, Bolch WE, Bouchet LG, Patton PW. Evolution and status of bone and marrow dose models. Cancer Biother Radiopharm 2002;17:427–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Coffey JL, Watson EE. Calculating dose from remaining body activity: a comparison of two methods. Med Phys 1979;6:307–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin’s lymphoma: combined data from four clinical trials. J Nucl Med 2003;44:465–74.PubMedGoogle Scholar
  16. 16.
    Snyder WS et al. Report of the task group on reference man. Pergamon Press, ICRP report No.23. Oxford, UK: International Commission on Radiological Protection; 1974.Google Scholar
  17. 17.
    Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma: from clinical trials to clinical practice. J Nucl Med 2002;43:1507–29.PubMedGoogle Scholar
  18. 18.
    ICRP 70, Basic anatomical and physiological data for use in radiological protection: the skeleton. ICRP publication 70. Oxford, UK: International Commission on Radiological Protection; 1995.Google Scholar
  19. 19.
    Patton JA, Delbeke D, Sandler MP. Image fusion using an integrated, dual-head coincidence camera with X-ray tube-based attenuation maps. J Nucl Med 2000;41:1364–68.Google Scholar
  20. 20.
    Knoos T, Nilsson M, Ahlgren L. A method for conversion of Hounsfield number to electron density and prediction of macroscopic pair production cross-sections. Radiother Oncol 1986;5:337–45.PubMedGoogle Scholar
  21. 21.
    Duck FA. Physical properties of tissue: a comprehensive reference book. New York: Academic Press; 1990.Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Department of Nuclear MedicineFremantle HospitalFremantleAustralia
  2. 2.School of Medicine and PharmacologyUniversity of Western AustraliaAustralia

Personalised recommendations